Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy

• Status: Completed
• Trial end date: 2012-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the efficacy of intravitreal bevacizumab injections for treatment of proliferative diabetic retinopathy (PDR) with new dense vitreous hemorrhage (VH) after previous full panretinal photocoagulation (PRP).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Khon Kaen University
• Treatments: Bevacizumab

Criteria

Inclusion Criteria:

• patients with diabetes mellitus

• proliferative diabetic retinopathy

• prior complete panretinal photocoagulation

• presented with new dense vitreous hemorrhage

Exclusion Criteria:

• one-eyed patient

• previous intraocular surgery

• severe lens opacity precluding fundus examination

• advance glaucoma

• history of thromboembolic events such as myocardial infarction and cerebrovascular accident

• uncontrolled systemic hypertension, systolic blood pressure > 180 mmHg or diastolic blood pressure > 110 mmHg

• known coagulation abnormalities or current use of anticoagulant medications other than aspirin

• known allergies to any relevant drugs in this study

• evidence of external ocular infection such as conjunctivitis and significant blepharitis.